Nektar Therapeutics Reports Second Quarter 2020 Financial Results

Rhea-AI Summary

Nektar Therapeutics (NKTR) reported Q2 2020 revenue of $48.8 million, significantly up from $23.3 million in Q2 2019, driven by a milestone payment of $25 million from Bristol-Myers Squibb. Cash and investments stood at $1.2 billion, down from $1.6 billion at year-end 2019 due to debt repayment. The net loss for Q2 was $80 million, or $0.45 per share, improving from a loss of $110.3 million in Q2 2019. The company has 5 ongoing registrational trials, with positive developments in immunotherapy and ongoing patient enrollment for NKTR-358 in lupus patients.

Positive

• Revenue increased 109% YoY to $48.8 million in Q2 2020.
• Cash reserves of $1.2 billion, no debt on the balance sheet.
• Five ongoing registrational trials for bempegaldesleukin.
• Positive Phase 1b data for NKTR-358 presented at EULAR 2020.
• Upcoming presentations at scientific events, showcasing ongoing research.

Negative

• Net loss in Q2 2020 was $80 million, despite YOY improvement.
• Operating costs increased to $310.8 million year-to-date, primarily due to NKTR-181 discontinuation.

SAN FRANCISCO, Aug. 6, 2020 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.

Cash and investments in marketable securities at June 30, 2020 were approximately $1.2 billion as compared to $1.6 billion at December 31, 2019. This decrease includes the repayment of $254.8 million for Nektar's senior secured notes and accrued interest, which occurred in the second quarter of 2020.

"During the second quarter, Nektar successfully advanced the registrational and early clinical trials across our immune-oncology portfolio which led to the opening of enrollment for the first patients into a new Phase 3 study in adjuvant melanoma for the bempegaldesleukin program," said Howard W. Robin, President and CEO of Nektar. "We now have 5 ongoing registrational trials for bempegaldesleukin, and we continue to make significant progress with our NKTR-262 and NKTR-255 clinical trials, with early data from these programs planned for presentation at this year's Society for Immunotherapy Congress in November."

Mr. Robin continued, "In immunology, following the positive Phase 1b data in lupus patients reported at EULAR, our partner Eli Lilly continues to expand their NKTR-358 development efforts. I am pleased to announce that they are initiating investigator sites and enrolling patients into a new Phase 2 study of NKTR-358 in moderate to severe systemic lupus erythematosus. We are fortunate to be entering the second half of 2020 in a position of exceptional strength – we have built a robust pipeline in oncology and immunology with multiple registrational and earlier stage clinical trials underway and we ended Q2 in a strong financial position with $1.2 billion in cash and investments, and no debt on our balance sheet."

Summary of Q2 2020 Financial Results

Revenue in the second quarter of 2020 was $48.8 million compared to $23.3 million in the second quarter of 2019. The increase was due to the recognition of the $25.0 million milestone from Bristol-Myers Squibb related to the recent initiation of the registrational trial of bempegaldesleukin plus Opdivo^® in adjuvant melanoma, which opened enrollment to patients in July. Year-to-date revenue for 2020 was $99.4 million compared to $51.5 million in the first half of 2019. Revenue was higher due to the recognition of $50.0 million in total milestones from Bristol-Myers Squibb related to the start of registrational trials of bempegaldesleukin plus Opdivo^® in adjuvant melanoma and muscle-invasive bladder cancer.

Total operating costs and expenses in the second quarter of 2020 were $126.6 million compared to $134.3 million in the second quarter of 2019. The decrease was due to a decrease in research and development (R&D) expense. Total operating costs and expenses in the first half of 2020 were $310.8 million compared to $283.2 million in the first half of 2019. Year-to-date operating costs and expenses increased primarily as a result of impairment of assets and other costs for NKTR-181, partially offset by a decrease in R&D expense. During the first quarter of 2020, Nektar reported $45.2 million in impairment charges and additional costs related to the discontinuation of the NKTR-181 program.

R&D expense in the second quarter of 2020 was $96.4 million compared to $106.7 million for the second quarter of 2019. For the first half of 2020, R&D expense was $205.4 million compared to $225.1 million in the first half of 2019. The decrease for both the second quarter and the first half of 2020 was due primarily to pre-commercial manufacturing costs for NKTR-181 incurred during the first half of 2019.

Net loss for the second quarter of 2020 was $80.0 million or $0.45 basic and diluted loss per share compared to a net loss of $110.3 million or $0.63 basic and diluted loss per share in the second quarter of 2019. Net loss in the first half of 2020 was $218.7 million or $1.23 basic and diluted loss per share compared to a net loss of $229.9 million or $1.32 basic and diluted loss per share in the first half of 2019.

Second Quarter 2020 and Recent Business Highlights:

• In June 2020, Nektar announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE). The data, which were presented during the Annual European Congress of Rheumatology (EULAR 2020) in a virtual congress format, showed that NKTR-358 was safe and well tolerated in patients with mild-to-moderate SLE and led to a marked and selective, dose-dependent expansion of regulatory T cells (Tregs) that was maintained over multiple administrations. 
• In May 2020, Nektar announced the publication of clinical data from its PIVOT-02 study evaluating bempegaldesleukin in combination with nivolumab in immunotherapy-naïve patients with advanced solid tumors, including melanoma, renal cell carcinoma and non-small cell lung cancer. The data, published in Cancer Discovery, a journal of the American Association for Cancer Research, showed that bempegaldesleukin plus nivolumab resulted in encouraging overall response rates across multiple tumor types, independent of baseline PD-L1 expression, with responses continuing to deepen over time.

The company also announced an upcoming presentation at the following scientific congress:

Cambridge Healthtech Institute's (CHI) 8^th Annual Immuno-Oncology Virtual Summit

• Presentation: "NKTR-255: A Potent NK and CD8 Memory T Cell Mobilizer for Immunotherapy", Madakamutil, L. 
• Session: Cytokines as Emerging Targets and Biotherapeutics
• Date: Thursday, October 8th, 9:40 a.m. – 10:00 a.m. Eastern Time

Conference Call to Discuss Second Quarter 2020 Financial Results
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, today, Thursday, August 6, 2020.

This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through August 31, 2020.

To access the conference call, follow these instructions:
   Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
   Passcode: 7858867 (Nektar Therapeutics is the host)

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements which can be identified by words such as: "may," "can," "develop," "progress," "will," "continue," "ensure," "preserve," "advance,"  "potential" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make concerning the potential therapeutic benefits of and future development plans for our investigational products (including bempegaldesleukin, NKTR-262, NKTR-255 and NKTR-358), our ability to safely advance and maintain the integrity of our clinical trials during the COVID-19 pandemic, and the strength of our financial position to develop our pipeline of our investigational products. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) the extent and duration of the impact of the COVID-19 pandemic on our business, regulatory efforts, research and development, clinical trials (including those being led by us and our partner), and corporate development activities will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, as well as the effectiveness of actions taken globally to contain and treat the disease; (ii) bempegaldesleukin, NKTR-262, NKTR-255 and NKTR-358 are investigational agents and continued research and development efforts for these drug candidates are subject to substantial risks, including negative safety and efficacy findings in ongoing clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to regulatory delays, decisions and policies of our partners, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iv) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (v) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2020. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:

For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661

For Media:
Dan Budwick of 1AB
973-271-6085
dan@1abmedia.com 

Opdivo is a registered trademark of Bristol-Myers Squibb Company.

 

 

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
ASSETS			June 30, 2020		December 31, 2019 (1)
Current assets:
	Cash and cash equivalents		$        58,206		$                96,363
	Short-term investments		980,191		1,228,499
	Accounts receivable		47,245		36,802
	Inventory		12,584		12,665
	Advance payments to contract manufacturers		15,972		31,834
	Other current assets		37,770		15,387
		Total current assets	1,151,968		1,421,550
Long-term investments			172,166		279,119
Property, plant and equipment, net			61,372		65,665
Operating lease right-of-use assets			131,458		134,177
Goodwill			76,501		76,501
Other assets			1,413		344
		Total assets	$   1,594,878		$            1,977,356
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
	Senior secured notes, net and interest payable		$               -		$               252,891
	Accounts payable		19,246		19,234
	Accrued compensation		22,548		11,467
	Accrued clinical trial expenses		42,794		32,626
	Accrued contract manufacturing expenses		11,050		7,304
	Other accrued expenses		11,424		12,338
	Operating lease liabilities, current portion		15,139		12,516
	Deferred revenue, current portion		1,757		5,517
		Total current liabilities	123,958		353,893
Operating lease liabilities, less current portion			141,633		142,730
Liability related to the sale of future royalties, net			68,284		72,020
Deferred revenue, less current portion			2,524		2,554
Other long-term liabilities			2,239		768
		Total liabilities	338,638		571,965
Commitments and contingencies
Stockholders' equity:
	Preferred stock		-		-
	Common stock		18		17
	Capital in excess of par value		3,338,876		3,271,097
	Accumulated other comprehensive income (loss)		715		(1,005)
	Accumulated deficit		(2,083,369)		(1,864,718)
		Total stockholders' equity	1,256,240		1,405,391
	Total liabilities and stockholders' equity		$   1,594,878		$            1,977,356

(1) The consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all  of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.

 

 

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share information)
(Unaudited)
			Three Months Ended June 30,				Six Months Ended June 30,
			2020		2019		2020		2019
Revenue:
Product sales			$      5,485		$      4,346		$      8,929		$      8,744
Royalty revenue			9,403		7,343		19,122		18,733
Non-cash royalty revenue related to sale of future royalties			7,684		9,091		17,579		17,321
License, collaboration and other revenue			26,275		2,535		53,790		6,739
Total revenue			48,847		23,315		99,420		51,537
Operating costs and expenses:
Cost of goods sold			5,773		5,018		9,584		10,458
Research and development			96,436		106,686		205,423		225,149
General and administrative			24,347		22,581		50,564		47,587
Impairment of assets and other costs for terminated program			-		-		45,189		-
Total operating costs and expenses			126,556		134,285		310,760		283,194
Loss from operations			(77,709)		(110,970)		(211,340)		(231,657)
Non-operating income (expense):
Interest expense			(647)		(5,231)		(6,851)		(10,457)
Non-cash interest expense on liability related to sale of future royalties			(6,691)		(5,975)		(13,659)		(12,040)
Interest income and other income (expense), net			5,191		11,989		13,543		24,472
Total non-operating income (expense), net			(2,147)		783		(6,967)		1,975
Loss before provision for income taxes			(79,856)		(110,187)		(218,307)		(229,682)
Provision for income taxes			144		99		344		236
Net loss			$   (80,000)		$ (110,286)		$ (218,651)		$ (229,918)
Basic and diluted net loss per share			$       (0.45)		$       (0.63)		$      (1.23)		$      (1.32)
Weighted average shares outstanding used in computing basic and diluted net loss per share			178,327		174,549		177,755		174,206

 

NEKTAR THERAPEUTICS
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
	Six Months Ended June 30,
	2020		2019
Cash flows from operating activities:
Net loss	$     (218,651)		$     (229,918)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to sale of future royalties	(17,579)		(17,321)
Non-cash interest expense on liability related to sale of future royalties	13,659		12,040
Stock-based compensation	48,607		49,907
Depreciation and amortization	7,692		6,132
Impairment of advance payments to contract manufacturers and equipment for terminated program	20,351		-
Accretion of premiums (discounts), net and other non-cash transactions	(782)		(6,329)
Changes in operating assets and liabilities:
Accounts receivable	(10,443)		5,914
Inventory	81		(1,807)
Operating leases, net	4,245		8,415
Other assets	(27,214)		15,818
Accounts payable	425		3,480
Accrued compensation	12,469		9,773
Other accrued expenses	8,952		15,794
Deferred revenue	(3,790)		(6,715)
Net cash used in operating activities	(161,978)		(134,817)
Cash flows from investing activities:
Purchases of investments	(543,631)		(603,702)
Maturities of investments	860,330		634,145
Sales of investments	41,700		-
Purchases of property, plant and equipment	(3,594)		(17,291)
Net cash provided by investing activities	354,805		13,152
Cash flows from financing activities:
Proceeds from shares issued under equity compensation plans	19,120		12,200
Repayment of Senior Notes	(250,000)		-
Net cash provided by (used in) financing activities	(230,880)		12,200
Effect of exchange rates on cash and cash equivalents	(104)		(16)
Net decrease in cash and cash equivalents	(38,157)		(109,481)
Cash and cash equivalents at beginning of period	96,363		194,905
Cash and cash equivalents at end of period	$       58,206		$       85,424
Supplemental disclosures of cash flow information:
Cash paid for interest	$         9,742		$         9,455
Operating lease right-of-use asset recognized in exchange for lease liabilities	$         2,133		$         1,289

 

View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-reports-second-quarter-2020-financial-results-301108006.html

SOURCE Nektar Therapeutics

FAQ

What was Nektar Therapeutics' revenue for Q2 2020?

Nektar Therapeutics reported a revenue of $48.8 million for Q2 2020.

What was the net loss for Nektar in Q2 2020?

Nektar had a net loss of $80 million in Q2 2020.

How much cash does Nektar have as of June 30, 2020?

As of June 30, 2020, Nektar had approximately $1.2 billion in cash and investments.

What are the ongoing trials for bempegaldesleukin?

Nektar has five ongoing registrational trials for bempegaldesleukin.

What developments occurred with NKTR-358 in 2020?

Nektar's partner Eli Lilly is initiating a Phase 2 study of NKTR-358 for systemic lupus erythematosus.